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Abstract 
Purpose: End-stage kidney disease (ESRD) patients under dialysis have high mortality 
rate. Inflammation, poor nutritional status and disturbances in erythropoiesis and iron 
metabolism have been reported in these patients. Moreover, there is a growing concern 
about the health related quality of life (HRQOL) in the context of ESRD. The aim of this 
work was to study the predictive value of these disturbances, dialysis adequacy and of 
HRQOL for mortality risk, by performing a three-year follow-up study. 
Methods: Clinical, socio-demographical and analytical data (dialysis adequacy, nutritional 
status, hematological data, lipid profile, iron metabolism and inflammatory markers) were 
obtained from 236 patients (61.02% male; 67.50 [56.00-75.00] years old) under online-
hemodiafiltration.	   Patient’s reported HRQOL score was assessed by using the Kidney 
Disease Quality of Life-Short Form (KDQOL-SF).  
 
Results: 54 patients died during the 3 years follow-up period. Our data showed that mean 
cell hemoglobin concentration (MCHC), transferrin and albumin are significant predictors 
of mortality. The risk of death was higher in patients presenting lower levels of MCHC 
(Hazard ratio [HR] = 0.70; 95% confidence interval [CI] = 0.500-0.984), transferrin (HR = 
0.99; 95% CI = 0.982 – 0.998), and albumin (HR = 0.96; 95% CI = 0.938-0.994). 
Conclusions: Our study showed that poor nutritional status and an inflammatory-induced 
iron depleted erythropoiesis are important factors for mortality in these patients. MCHC, 
transferrin and albumin may provide useful biomarkers of risk in ESRD patients under OL-
HDF. 
 
Keywords: End-stage kidney disease, online-hemodiafiltration, health-related quality of 
life, mortality, nutritional status, iron metabolism, inflammation 
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Resumo 
Introdução: Indivíduos com doença renal terminal em hemodiafiltração apresentam uma 
taxa de mortalidade elevada. Inflamação, estado nutricional deteriorado e alterações na 
eritropoiese e no metabolismo do ferro têm sido descritas nestes doentes. Além disso, a 
qualidade de vida relacionada à saúde (QVRS) tem vindo a ser uma preocupação 
crescente no contexto desta doença. O objectivo deste trabalho foi o de identificar 
possíveis associações entre mortalidade e as alterações anteriormente descritas e com a 
QVRS, realizando um follow-up de três anos. 
Métodos: Dados sociodemográficos, clínicos e analíticos (marcadores de adequação de 
diálise, nutricionais, hematológicos, inflamatórios, perfil lipídico e metabolismo do ferro) 
foram obtidos de 236 doentes [61.02% homens; 67.50 (56.00-75.00) anos de idade] que 
estavam em terapêutica dialítica pela técnica de hemodiafiltração online. A QVRS 
reportada pelos doentes foi avaliada através do instrumento Kidney Disease Quality of 
Life-Short Form. 
Resultados: 54 pacientes morreram durante os 3 anos de seguimento. Os dados do 
nosso estudo mostraram que a concentração de hemoglobina corpuscular média 
(CHCM), transferrina e albumina são preditores significantes de mortalidade. O risco de 
morte foi maior em pacientes que se apresentaram com valores menores de CHCM 
(Razão de riscos [RR] = 0.70; 95% intervalo de confiança [IC] = 0.500-0.984), transferrina 
(RR = 0.99; 95% IC = 0.982 – 0.998) e albumina (RR = 0.96; 95% IC = 0.938-0.994). 
Conclusões: O nosso estudo demonstrou que o mau estado nutricional e uma 
eritropoiese deficiente em ferro induzida pelo estado inflamatório são factores associados 
com mortalidade nestes doentes. A CHCM, transferrina e albumina poderão ser 
biomarcadores de risco importantes nos doentes renais terminais em hemodiafiltração 
 
Palavras Chave: Doença renal terminal, hemodiafiltração, qualidade de vida relacionada 
à saúde, estado nutricional, metabolismo do ferro, inflamação 
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Introduction 
End-stage kidney disease (ESRD) is a growing health public problem, given the 
increasing prevalence worldwide and its socio-economic consequences. By 2020, it is 
estimated that the number of ESRD patients rise by 60%, as compared to the number of 
patients registered in 2005.1 Mortality rate for ESRD patients is 10 to 20 fold higher2, 3 
when compared with general population.4 
Hemodialysis (HD), widely used during the past half-century, brought forth a way to 
lengthen ESRD patients’ lives. Nonetheless, it is poorly suited to the effective removal of 
larger solutes, such as β2 microglobulin. In recent years, online-hemodiafiltration (OL-
HDF) was introduced as an alternative to standard HD, as it was claimed that OL-HDF 
would be more biocompatible, would increase dialysis efficacy and reduce the 
inflammatory response – features that would diminish the risk of morbidity and mortality in 
ESRD.5 However, a recent meta-analysis of randomized trials, comparing the effect of OL-
HDF with traditional HD on ESRD patient’s mortality, showed that the potential benefits of 
convective modalities over standard HD, for mortality, remain unproved.6 
In spite of the technological and pharmacological advances achieved in the last decade 
for the treatment of ESRD patients, survival is still low. Cardiovascular disease (CVD) has 
been considered the most common cause of death in these patients7 and this may be 
connected with the high prevalence of classic cardiovascular risk factors, which include 
hypertension, diabetes mellitus, dyslipidemia, smoking and advanced age. In addition, 
several uremia-related factors may also play an important role, namely the presence of 
multiple comorbid conditions, fluid overload, hyperphosphoremia, oxidative stress, 
anemia, endothelial dysfunction, left ventricular hypertrophy, insulin resistance, hyper-
homocysteinemia, high levels of lipoprotein(a) and an enhanced inflammatory state.8-11 
Cardiac arrest and congestive heart failure are more prominent causes of cardiovascular 
death than acute myocardial infarction in patients with uremia. 
Dialysis is associated with symptoms that affect the daily life, and there is evidence that 
patients consider the health-related quality of life (HRQOL) more important than survival 
itself.12 HRQOL is a multidimensional concept and its assessment through disease 
specific questionnaires has reported HRQOL as a strong and independent predictor of 
mortality in ESRD patients.13-15 
In order to evaluate potential predictors of mortality, useful in clinical setting, we evaluated 
the global mortality in a group of Portuguese ESRD patients under OL-HDF, by 
performing a follow-up study of three years. In this work several variables were included 
as potential predictors of mortality, including clinical, socio-demographic and analytical 
data (dialysis adequacy, nutritional status, hematological data, lipid profile, iron 
metabolism and inflammatory markers), as well as the different domains and component 
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summaries of HRQL by using Kidney Disease Quality of Life Short Form (KDQOL-SF) 
instrument.  
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Material and Methods 
Patients and study design 
This is a three-year follow-up study, which started in April 2012, and included 236 ESRD 
patients (61.02% males; 65.29 ± 13.38 years old) from 5 dialysis clinics in the northern 
region of Portugal, under OL-HDF three times per week, for 3-5 hours. The main causes 
of renal failure, in this group of patients, were diabetic nephropathy (n=100), hypertensive 
nephrosclerosis (n=41) and other diseases and/or uncertain etiology (n=95).  
Patients were excluded if they: (1) did not accept to participate in the study; (2) were 
cognitively impaired; (3) were under 18 years old; (4) had a severe speech or hearing 
impairment; (5) were in the dialysis program for less than three months; (6) presented with 
malignancy, autoimmune diseases, and inflammatory or infectious diseases.  
Patients were clinically evaluated and blood samples were collected at the beginning of 
the study; KDQOL-SF questionnaire was self-administered to all patients. The 
questionnaire was completed by the patients themselves, except blind or disabled 
patients; in these cases the questionnaire was filled with the help of a family member or of 
their physician at the dialysis clinic. 
For OL-HDF procedure, Fresenius Medical Care dialysis machines (model 5008) and 
synthetic high-flux polysulfone dialyzers (Fresenius Medical Care, Bad Hamburg, 
Germany) were used. 
The study was approved by the Ethics Committee of Fresenius Medical Care - Portugal, 
and written informed consent was obtained from all participants. 
 
Assays 
Blood samples were obtained immediately before the OL-HDF procedure in the midweek 
dialysis day and processed within 2 hours after collection. Blood was collected to tubes 
with EDTA and without anticoagulant, in order to obtain whole blood, plasma and serum. 
Aliquots were immediately stored at -80ºC, whenever necessary, until assayed. 
Erythrocyte count, hematocrit, hemoglobin concentration and red blood cell indices [mean 
cell volume (MCV), mean cell hemoglobin (MCH), and mean cell hemoglobin 
concentration (MCHC)] were measured using an automatic blood cell counter (Sysmex 
K1000; Sysmex, Hamburg, Germany). Leukocyte differential counts were evaluated in 
Wright-stained blood films. Reticulocyte count was made by microscopic counting on 
blood smears after vital staining with New methylene blue (reticulocyte stain; Sigma, St. 
Louis, MO, USA). 
Serum iron concentration was determined using a colorimetric method (Iron, Randox 
Laboratories Ltd., Northern Ireland, UK); serum ferritin and transferrin were measured by 
immunoturbidimetry (Ferritin, Randox Laboratories Ltd., Northern Ireland UK; Transferrin, 
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Randox Laboratories Ltd., Northern Ireland, UK); transferrin saturation (TS) was 
calculated using the formula: TS (%) = 70.9 x serum iron concentration (mg/dL)/serum 
transferrin concentration (mg/dL). 
C-reactive protein (CRP) was evaluated by immunoturbidimetry, using commercially 
available kits [CRP (latex) High-Sensitivity, Roche Diagnostics, Mannheim, Germany]. 
Serum total cholesterol and triglycerides concentrations were evaluated by enzymatic 
colorimetric tests (cholesterol oxidase-phenol aminophenazone and glycerol-3-phosphate 
oxidase-phenol aminophenazone methods, Roche, Basel, Switzerland). Low-density 
lipoprotein cholesterol (LDLc) and high-density lipoprotein cholesterol (HDLc) levels were 
measured using enzymatic colorimetric tests, after selective separation of LDLc and HDLc 
fractions (Direct LDLCholesterol and Direct HDLCholesterol, Roche, Basel, Switzerland). 
Serum albumin levels were measured using a colorimetric assay end-point (Albumin Plus; 
Roche GmbH, Mannheim, Germany). Body mass index (BMI) was calculated using the 
formula: BMI = mass (kg)/height2 (m). 
All remaining analytical parameters were measured using standard laboratorial 
techniques.  
 
Kidney Disease Quality of Life Questionnaire-Short Form 
The KDQOL-SF has become the most widely used QOL assessment tool for ESRD 
patients. Since its development in the USA16, it has been translated into several other 
languages and applied in other countries, namely in Portugal.17-19 
HRQOL was measured using the KDQOL-SF 1.3 for the Portuguese population, which 
includes a kidney disease-specific part (KDQOL) and a generic 35 question-part (SF-36 
version 2). The latter is divided into eight domains: patient’s physical functioning (10 
items); role physical (4 items); pain (2 items); general health (5 items), emotional well-
being (5 items); role-emotional (3 items); social functioning (2 items); and energy and 
fatigue (4 items). Each domain is scored from 0 to 100, increasing the score with a better 
quality of life. Mental component summary (MCS) and physical component summary 
(PCS) result from the scores of these eight different SF-36 domains: PCS includes 
physical functioning, role-physical, pain and general health; MCS includes vitality, social 
functioning, role-emotional and mental health. 
The KDQOL part is made up by 43 kidney disease-targeted questions, divided by 11 
domains: symptom/problems (12 items), effects of kidney disease (8 items), burden of 
kidney disease (4 items), work status (2 items), cognitive function (3 items), quality of 
social interaction (3 items), sexual function (2 items), sleep (4 items), social support (2 
items), staff encouragement (2 items) and patient satisfaction (1 item).  
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Statistical analysis 
Kolmogorov-Smirnov test was used to test the variable distributions for normality; normally 
distributed variables are presented as mean ± standard deviation (SD), whereas non-
normal data are presented as median [interquartile range (IQR)]. Patients were 
categorized at the end of the three years of follow-up as “Alive after follow-up” and 
“Deceased during follow-up”. Differences between groups were analyzed by using 
Student t-test or Mann-Whitney test, according to distribution of the variables, evaluated 
by Kolmogorov-Smirnov test. Adjustment for confounding factors (age and previous time 
in dialysis) was performed using ANCOVA.  The association between categorical 
variables was analyzed using the chi-squared test or Fisher’s exact test. 
Mental and physical component summaries of SF-36 were calculated according to 
Ferreira et al methodology.20 It included a Z-score transformation for each dimension, 
followed by an arithmetic component (*10+50), added after the sum of the Z-transformed 
corresponding dimensions.  
Survival analysis, considering the competing risk and the event of interest, was performed 
to analyze patient’s survival. The event of interest was death and the competing risk event 
was renal transplantation. Cumulative incidence function was estimated. Regression 
models, considering the competing risk (Fine and Gray model based on subdistribution 
hazard model), were carried out, to analyze the effect of covariates in patient’s survival. 
To decide which variables should be included in the final multivariable model, an 
exploratory analysis was performed by fitting models for each variable, adjusting for age 
and previous time in dialysis. The final multivariable model included all of the candidate 
variables, presenting with p values <0.1. All analyses were performed with SPSS and R 
software using the packages cmprsk, and significance level (α) was set at 0.05. 
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Results 
During the period from April 2012 through April 2015, 54 patients (22.88%) died and 40 
(16.95%) received kidney transplant. The probability of death by 6, 12, 24 and 36 months 
after starting the study was 0.025, 0.073, 0.147 and 0.236, respectively; figure 1 illustrates 
cumulative incidence curves that estimate the possible events – death, as event of 
interest, and transplantation as competing risk. 
	  
 
 
Figure 1: Cumulative incidence curves for all possible events (death as event of interest and 
kidney transplant as competing risk) for ESRD patients. CIF: cumulative incidence function 
 
Tables I displays sociodemographic and clinical data, as well as markers of dialysis 
adequacy; in Table II, hematological data, markers of iron metabolism and inflammation, 
the lipid profile and markers of nutritional status, are presented; the various HRQOL 
domain values, assessed by using the KDQOL-SF, are presented in Table III. The values 
at baseline are presented for all patients and for those patients who were alive or 
deceased, by the end of the follow-up period. 
Patients who died along the study showed significantly lower values for creatinine, uric 
acid, urea, MCHC, transferrin, triglycerides and albumin; significantly higher values were 
found for RDW and CRP. Moreover, older age and the use of CVC as vascular access for 
dialysis were also significantly associated with death. As for the HRQOL, lower values of 
physical functioning, role-physical, pain, emotional well-being, role-emotional, 
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energy/fatigue and PCS were observed at baseline for the patients who died during the 
follow-up period; a trend towards a lower quality of social interaction was also observed. 
 
Table I – Sociodemographic, clinical data, and dialysis adequacy, at baseline, for alive and deceased 
patients, at the end of the follow-up period. 
 
Baseline values 
(n=236) 
 
Alive after follow-up 
(142 patients) 
 
Deceased during 
follow-up 
(54  patients) 
p value 
Clinical data; biochemical and dialysis markers 
Age, years 67.50 (56.00-75.00) 67.00 (55.25-75.00) 74.00 (68.00-81.00) <0.001 
Gender (male), n(%) 144 (61.02) 82 (57.75) 31 (57.41) 0.925 
Previous time on dialysis, 
months 
32.00 (11.25-60.75) 30.00 (10.00-60.25) 35.00 (11.50-91.00) 0.284 
Diabetic patients, n (%) 101 (42.80) 64 (45.07) 27 (50.00) 0.797 
Hypertensive patients, n (%) 41 (17.37) 21 (14.79) 8 (14.82) 0.996 
CVC use, n (%) 55 (23.31) 30 (21.13) 19 (35.20) 
0.045 
FAV use, n (%) 181 (76.69) 112 (78.87) 35 (64.80) 
URR, % 76.78 ± 5.75 77.37 ± 5.42 75.84 ± 6.35 0.10 
KT/Ve 1.52 ± 0.30 1.55 ± 0.30 1.47 ± 0.30 0.08 
Creatinine, mg/dL 7.74 ± 3.16  7.82 ±3.13 6.44 ± 3.02 0.01 
Potassium, mmol/L 5.21 ± 0.85 5.18 ± 0.81 5.08 ± 0.92 0.45 
Sodium, mmol/L 
137.00 (135.00-
139.00) 
137.00 (135.00-
139.00) 
136.00 (133.00-
139.00) 
0.30 
Phosphorus, mmol/L 4.23 ± 1.31 4.30 ± 1.39 4.08 ± 1.17 0.31 
Calcium, mg/dL 8.58 ± 0.60 8.60 ± 0.65 8.51 ± 0.48 0.28 
Calcium phosphorus product  36.29 ±11.55 36.96 ± 12.43 34.76 ± 9.96 0.25 
Uric Acid, mg/dl 6.72 ± 1.31 6.75 ±1.17 6.15 ± 1.29 0.01 
Urea, mg/dl 
136.00 (111.50-
161.50) 
137.00 (116.00-
168.00) 
127.00 (104.50-
150.50) 
0.02 
PTHi, pg/ml 
327.00 (179.50-
520.50) 
344.00 (188.50-
525.00) 
297.50 (170.25-
530.75) 
0.89 
Aluminum, µg/L 4.05 (3.00-5.50) 4.20 (3.00-5.50) 4.80 (3.28-6.00) 0.22 
Darbopoeitin, µg/kg/week 0.34 (0.19-0.54) 0.33 (0.19-0.49) 0.39 (0.19-0.73) 0.249 
 
Data are presented as mean (± standard deviation) or as median (interquartile range). CVC: Central venous 
catheter; AVF: Arteriovenous fistula; URR: urea reduction ratio; KT/Ve: dialyzer clearance of urea by dialysis 
time/volume of distribution of urea; PTHi: intact parathyroid hormone; CRP: C-reactive protein. 
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Table II - Hematological data, markers of iron metabolism and inflammation, lipid profile and markers of 
nutritional status,	  at baseline, for alive and deceased patients, at the end of the follow-up period. 
Data are presented as mean (± standard deviation) or as median (interquartile range). MCV: mean cell volume; 
MCH: mean cell hemoglobin; MCHC: mean cell hemoglobin concentration; RDW: red cell distribution width; 
HDLc: high-density lipoprotein cholesterol; LDLc: low-density lipoprotein cholesterol; nPCR: normalized protein 
catabolic rate. 
  
 
Baseline values 
(n=236) 
 
Alive after follow-up 
(142 patients) 
 
Deceased during 
follow-up 
(54  patients) 
p 
value 
Hematological data 
Erythrocytes, x1012/L 3.74 (3.50-4.14) 3.73 (3.56-4.11) 3.78 (3.61-4.22) 0.12 
Hemoglobin, g/dL 11.68 ± 1.36 11.65 ± 1.31 11.62 ± 1.43 0.88 
Hematocrit, % 35.95 ± 4.23 35.70 ± 4.04 36.14 ± 4.40 0.51 
MCV, fL 95.09 ± 6.03 95.05 ± 5.79 94.44 ± 6.86 0.53 
MCHC, g/dL 32.49 ± 1.13 32.62 ± 1.08 32.12 ± 1.11 <0.001 
MCH, pg 30.50 ± 4.12 30.57 ± 4.24 29.77 ±4.84 0.26 
RDW, % 14.55 (13.70-15.60) 14.20 (13.50-15.40) 15.30 (14.00-16.50) 0.01 
Platelets, x10 9/L 179.29 ± 60.89 179.44 ± 57.44 173.09 ± 67.48 0.23 
Leukocytes, x10 9/L 6.00 (4.95-6.37) 5.84 (5.00-7.28) 6.18 (5.11-7.88) 0.21 
Neutrophils, x10 9/L 3.75 (3.02-4.66) 3.66 (3.00-4.53) 3.87 (3.07-5.04) 0.35 
Lymphocytes, x10 9/L 1.45 (1.15-1.95) 1.47 (1.17-1.94) 1.45 (1.09-2.04) 0.79 
Neutrophil/lymphocyte ratio 2.50 (1.80-3.40) 2.50 (1.80-3.28) 2.70 (2.05-3.80) 0.22 
Iron metabolism markers 
Transferrin, mg/dL 209.47 ± 96.37  223.55 ± 117.05 179.94 ± 46.14 0.01 
Transferrin saturation, % 24.00 (19.31-32.92) 25.00 (19.37-33.00) 23.00 (18.40-36.00) 0.97 
Iron, µg/dL 65.00 (50.00-84.25) 66.50 (51.75-85.25) 62.50 (41.25-82.00) 0.16 
Ferritin, ng/mL 350.75 (211.00-474.25) 324.90 (206-480.50) 389.80 (327.35 -480.70) 0.66 
Inflammatory markers 
CRP, mg/dL 4.40 (2.10-10.23) 4.00 (1.90-9.10) 6.65 (3.55-19.95) <0.001 
Lipid profile 
Total cholesterol, mg/dL 149.00 (125.00-177.00) 148.00 (125.00-181.00) 147.50 (124.25-172.75) 0.56 
Triglycerides, mg/dL 122.00 (87.00-188.00) 122.00 (90.00-182.00) 100.00 (76.50-166.00) 0.04 
HDLc, mg/dL 43.00 (35.00-50.00) 43.00 (35.00-47.00) 43.00 (35.00-54.00) 0.42 
LDLc, mg/dL 80.20 (66.00-100.00) 82.40 (65.40-106.40) 79.20 (63.80-93.40) 0.38 
Nutritional markers 
BMI, Kg/m2 25.69 ± 4.53 25.74 ± 4.74 25.53 ± 4.22 0.78 
Albumin, g/dL 40.00 (36.85-48.50) 41.00 (37.20-47.00) 37.80 (35.00-40.30) <0.001 
nPCR, g/kg/day 1.17 (1.07-1.50) 1.18 (1.08-1.40) 1.11 (1.02-1.28) 0.11 
Total protein, g/dL 7.20 (6.50-66.00) 7.20 (6.50-67.75) 7.00 (6.28-64.00) 0.10 
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Table III - HRQOL domains based on the KDQOL-SF, at baseline, for alive and deceased patients, 
at the end of the follow-up period. 
 
Baseline 
values 
(n=236) 
 
Alive after 
follow-up 
(142 patients) 
 
Deceased during 
follow-up 
(54 patients) 
p value 
ESRD–targeted Areas 
Symptoms/problem list 74.93 ± 16.60 76.72 ±15.53 72.05 ± 17.47 0.07 
Effects of kidney disease 65.53 ± 21.69 67.93 ± 20.88 64.62 ± 20.20 0.33 
Burden of kidney disease 24.44 ± 23.66 26.16 ±24.20 22.34 ± 22.31 0.32 
Work status 12.45 ± 27.77 11.79 ± 27.88 10.38 ± 22.70 0.74 
Cognitive function 77.37 ± 19.70 78.53 ± 17.95 72.22 ± 24.63 0.10 
Quality of social interaction 80.89 ± 19.19 81.12 ±18.80 75.82 ±19.95 0.09 
Sexual function 79.48 ± 24.10 83.93 ± 20.73 79.17 ± 26.02 0.70 
Sleep 40.53 ± 15.50 41.33 ± 14.30 42.48 ± 17.80 0.67 
Social support 82.12 ± 27.01 83.33 ±25.96 78.21 ± 27.92 0.23 
Dialysis care 
Staff encouragement 88.37 ± 21.77 90.04 ± 15.59 87.97 ± 21.51 0.53 
Patient satisfaction 56.37 ± 22.45 57.50 ± 22.38 51.85 ± 21.88 0.12 
36-item health survey (SF-36) 
Physical functioning 43.89 ± 30.92 40.09 ± 30.76 28.33 ± 27.27 <0.001 
Role-physical 24.34 ±31.15 27.13 ±32.11 16.09 ± 27.89 0.03 
Pain 63.32 ±29.24 66.13 ± 27.13 53.69 ± 34.23 0.02 
General health 35.52 ±20.98 35.84 ± 21.14 35.11 ± 20.37 0.83 
Emotional well-being 60.30 ± 24.83 62.25 ± 23.89 54.17 ± 25.77 0.04 
Role-emotional 44.64 ± 32.23 47.90 ±31.35 35.93 ± 33.98 0.02 
Energy/ Fatigue 46.99 ± 19.35 48.59 ± 18.54 41.11 ± 20.30 0.02 
Social function 67.98 ± 34.12 68.79 ± 33.09 60.88 ±37.07 0.15 
Physical and mental components summaries of SF-36 
PCS 49.82 ± 9.14 50.80 ± 9.55 46.79 ± 7.83 0.003 
MCS 49.82 ± 9.67 50.22 ± 9.75 48.03 ± 10.01 0.168 
Data are presented as mean (± standard deviation). PCS: physical component summary; MCS: mental 
component summary
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Univariate analysis 
Univariate analysis using the Fine and Gray regression model, adjusted for age and 
previous time under OL-HDF (Table IV), shows that lower values of creatinine, urea, 
MCHC, transferrin, albumin, role-physical, pain, emotional well-being, role-emotional, 
energy/fatigue, cognitive function and symptom/problems, as well as a higher value of 
RDW were significantly linked with mortality. 
 
Table IV- Survival regression model for ESRD patients’ mortality, adjusted for age 
and previous time under OL-HDF (univariate analysis) 
 
Adjusted 
hazard ratio 
 
95% CI 
 
p value 
Role physical 0.989 0.977-1.00 0.043 
Pain 0.989 0.980-0.997 0.009 
Emotional well being 0.988 0.978-0.998 0.015 
Role emotion 0.989 0.980-0.998 0.015 
Energy fatigue 0.982 0.967-0.997 0.021 
Cognitive function 0.987 0.974-1.00 0.046 
Symptom/problems 0.986 0.972-0.999 0.040 
Urea 0.990 0.982-0.999 0.027 
MCHC 0.645 0.486-0.885 0.002 
RDW 1.360 1.147-1.600 <0.001 
Transferrin 0.991 0.983-0.999 0.025 
Albumin 0.962 0.935-0.999 0.008 
Creatinine 0.875 0.797-0.961 0.005 
MCHC: mean cell hemoglobin concentration; RDW: red cell distribution width; CI: 
confidence interval. 
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Multivariate analysis 
Survival regression models, adjusted for age and previous time in HD, are presented in 
Table V. This analysis showed that MCHC, transferrin and albumin are significant 
predictors of the event of interest, death. Indeed, the risk of death is higher in patients that 
presented lower levels of MCHC, transferrin and albumin.  
 
Table V- Survival regression model for ESRD patients’ mortality, adjusted for age 
and previous time under OL-HDF (multivariate analysis) 
 
Adjusted 
hazard 
ratio 
 
95% CI 
 
p value 
MCHC 0.702 0.500-0.984 0.040 
Transferrin 0.990 0.982-0.998 0.010 
Albumin 0.966 0.938-0.994 0.018 
MCHC: mean cell hemoglobin concentration; CI: confidence interval. 
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Discussion 
In this 3-year follow-up study, 236 ESRD patients under OL-HDF were evaluated 
with the intent of identifying parameters that might me associated with mortality in 
the context of that disease and, therefore, provide useful biomarkers in the clinical 
setting. 
During the follow-up period, 54 patients (22.88%) died and 40 (16.95%) received 
kidney transplant. Several variables were remarkably different, when comparing 
the baseline values presented by patients who were alive at the end of the study, 
with those of the patients who died during the follow-up study.  
We found that the patients who died showed lower levels of creatinine, urea and 
uric acid. In general population, a slight or moderate increase in serum creatinine 
has been shown to be an independent risk factor of cardiovascular disease. In 
ESRD patients under dialysis, serum creatinine concentration is dependent on 
muscle mass, meat ingestion and on the degree of dialysis efficiency In 
accordance with our results, it has been reported that creatinine is inversely 
correlated with the risk for death (i.e., those dialysis patients with a higher serum 
creatinine live longer).21, 22 Actually, our data suggests that the reduction in 
creatinine results, particularly, from malnutrition. This hypothesis is strengthened 
by the significantly lower values of TG and albumin concentrations, also observed 
in these patients. Moreover, these patients also showed erythropoietic 
disturbances, namely iron metabolism, as showed by the significantly lower values 
of transferrin and MCHC, as well as a higher RDW value; these erythropoietic 
changes are probably due to an enhanced inflammatory state, as showed by the 
significantly higher CRP value in these patients, when compared to the living 
patients. The presence of inflammatory features are well documented in literature 
are known to reduce iron absorption and iron mobilization, explaining the lower 
erythrocyte hemoglobinization, the reduction in transferrin and the trends towards 
a reduction in transferrin saturation and serum iron, as well as the increase in 
ferritin. The increase in RDW probably reflects these disturbances and the severity 
of the disease. Actually, these patients also presented a trend (p=0.08) towards 
lower KT/Ve, showing a lower dialysis efficacy. 
Considering HRQOL, patients who died during the follow up showed remarkably 
poor scores for most of the SF-36 domains. The low scores for physical 
functioning, role-physical, pain, emotional well-being, role-emotional, 
energy/fatigue and PCS reflects a decreased functional capacity and physical 
limitations in daily activities, which might contribute to a lower quality of social 
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interaction (p=0.09). These results are in accordance with previous studies on 
HRQOL in ESRD patients.23 
By performing a multivariate analysis, we observed that the values for MCHC, 
transferrin and albumin were independently associated with all-cause mortality. 
Serum albumin concentration has been shown to be a powerful predictor for 
mortality in patients under dialysis24 and our results match with previous reports in 
literature. The lower albumin values are also reflective of a poor nutritional status 
that may be linked to a malnutrition-inflammatory complex syndrome25 or to a 
catabolic state associated with dialysis. Meanwhile, it has been reported that 
nutritional interventions to increase serum albumin may lead to considerable 
improvements in mortality rate.26 
An increase in the inflammatory state of patients under dialysis has been proposed 
as an important mortality risk factor in these patients. 27 Inflammatory markers can 
be used, therefore, as predictors of death. In our study, CRP values were higher in 
deceased patients; however, survival regression models did not show CRP as an 
independent risk factor. As already referred, inflammation interferes with iron 
metabolism through hepcidin28, reducing the mobilization and absorption of iron, 
needed for erythropoiesis. This leads to worsening of anemia, a common finding in 
these patients. Our survival regression models showed MCHC and transferrin as 
independent risk factors for mortality, and, therefore, that inflammatory-induced 
iron depleted erythropoiesis, should be carefully monitored in ESRD patients. 
Another recently reported study29 from our research group, involving a lower 
number of ESRD patients and a smaller follow-up period, evaluated the predictive 
value of several analytical parameters; in that study, inflammatory markers and 
nutritional status were also found as predictors for mortality in ESRD patients.  
The bulk of literature concerning risk factors for mortality in ESRD patients usually 
assesses standard analytical data; indeed, only a few studies considered HRQOL 
as a possible death predictor. In the present study, we brought together both areas 
and, while univariate analysis results showed several HRQOL domains 
significantly associated with mortality, none of them was identified as an 
independent risk factor after the multivariate analysis. 
Evaluation of the patients’ perception of HRQOL was, actually, a key aspect of our 
study, and strongly showed that HRQOL is more important for the patient than 
survival itself. A previous study reported that HRQOL should be considered an 
independent factor for mortality in ESRD patients30. In opposition, our data showed 
that the patients who died presented poorer HRQOL, as showed by the scores in 
the KDQOL-SF, reflecting the worsening of the general health status of ESRD 
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patients. Moreover, according to our results, HRQOL domains might be used to 
gauge the progression of the disease, but they are not independently linked to 
death. They are particularly important to access how the changes brought by 
ESRD affect the HRQOL, perceived by the patients.31 
This study presented some limitations, namely the reduced number of patients 
included and a relatively limited follow-up period. Plus, CRP was the only major 
inflammatory marker measured and, if other markers were evaluated, we might 
have assessed inflammation more thoroughly, in ESRD patients. 
In conclusion, our study showed that the nutritional status and an inflammatory-
induced iron depleted erythropoiesis are important factors for the survival of these 
patients, and that MCHC, transferrin and albumin may provide useful biomarkers 
of risk in ESRD patients under OL-HDF. 
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